EP0897300A4 - Treatment of pruritus with vitamin d and analogs thereof - Google Patents

Treatment of pruritus with vitamin d and analogs thereof

Info

Publication number
EP0897300A4
EP0897300A4 EP96935864A EP96935864A EP0897300A4 EP 0897300 A4 EP0897300 A4 EP 0897300A4 EP 96935864 A EP96935864 A EP 96935864A EP 96935864 A EP96935864 A EP 96935864A EP 0897300 A4 EP0897300 A4 EP 0897300A4
Authority
EP
European Patent Office
Prior art keywords
pruritus
analogs
vitamin
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96935864A
Other languages
German (de)
French (fr)
Other versions
EP0897300A1 (en
Inventor
Marilyn Strube
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0897300A1 publication Critical patent/EP0897300A1/en
Publication of EP0897300A4 publication Critical patent/EP0897300A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP96935864A 1995-10-10 1996-09-18 Treatment of pruritus with vitamin d and analogs thereof Withdrawn EP0897300A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US503095P 1995-10-10 1995-10-10
US5030P 1995-10-10
PCT/US1996/015016 WO1997013518A1 (en) 1995-10-10 1996-09-18 Treatment of pruritus with vitamin d and analogs thereof

Publications (2)

Publication Number Publication Date
EP0897300A1 EP0897300A1 (en) 1999-02-24
EP0897300A4 true EP0897300A4 (en) 2000-07-05

Family

ID=21713776

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96935864A Withdrawn EP0897300A4 (en) 1995-10-10 1996-09-18 Treatment of pruritus with vitamin d and analogs thereof

Country Status (5)

Country Link
US (2) US5789399A (en)
EP (1) EP0897300A4 (en)
JP (1) JPH11514999A (en)
AU (1) AU7364896A (en)
WO (1) WO1997013518A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225431B1 (en) * 1991-07-05 2001-05-01 Biocompatibles Limited Biocompatibilizing process
US6284854B1 (en) * 1991-07-05 2001-09-04 Biccompatibles Limited Polymeric surface coatings
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
ZA991856B (en) 1998-08-27 1999-09-22 Henkel Corp Storage-stable compositions useful for the production of structural foams.
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
LT2915534T (en) * 1999-04-23 2018-06-25 Leo Pharma A/S Pharmaceutical composition for dermal use to treat psoriasis comprising a vitamin D and a corticosteroid
US6423746B1 (en) * 1999-07-03 2002-07-23 The William M. Yarbrough Foundation Urushiol induced contact dermatitis and method of use
US6117904A (en) * 1999-09-03 2000-09-12 Murphy; Donald M. Treatment of pruritus
US6541517B1 (en) 1999-09-03 2003-04-01 Donald M. Murphy Treatment of skin disorders
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
JP2004504295A (en) * 2000-07-18 2004-02-12 ボーン　ケア　インターナショナル　インコーポレイテッド Stabilized 1α-hydroxyvitamin D
EP1539104A4 (en) * 2000-12-29 2005-06-15 Univ Columbia Use of iv emulsions with different triglyceride composition, particle size and apolipoprotein e for targeted tissue delivery of hydrophobic compounds
US20030018095A1 (en) * 2001-04-27 2003-01-23 Agarwal Rajat K. Thermosettable compositions useful for producing structural adhesive foams
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20080020025A1 (en) * 2003-08-28 2008-01-24 Pharmaionx, Inc. Composition for wound care and method of using same
WO2005115403A2 (en) * 2004-05-26 2005-12-08 Cedars-Sinai Medical Center Induction of innate immunity by vitamin d3 and its analogs
US20060073107A1 (en) * 2004-10-04 2006-04-06 Person John R Use of vitamin D3 (cholecalciferol) in sunscreens
US20060172951A1 (en) * 2005-01-28 2006-08-03 Dantzig Paul I Age related macular degeneration and cutaneous signs of mercury toxicity
ES2525410T3 (en) * 2005-05-10 2014-12-22 Dermipsor Ltd Compositions and methods for the treatment of dermal hyperproliferative diseases
EP1917072B1 (en) * 2005-06-01 2013-02-27 Stiefel Research Australia Pty Ltd Vitamin formulation
FR2893847B1 (en) * 2005-11-30 2010-10-29 Galderma Sa SPRAY COMPOSITION COMPRISING VITAMIN D DERIVATIVE AND OILY PHASE
US20070203040A1 (en) * 2006-02-24 2007-08-30 Harry Reicherz Bar soap
WO2008027532A2 (en) * 2006-08-29 2008-03-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions including vitamin d and corticosteroid
TWI433674B (en) 2006-12-28 2014-04-11 Infinity Discovery Inc Cyclopamine analogs
US20090017129A1 (en) * 2007-07-13 2009-01-15 Ma Or Ze Ev Dead Sea minerals enriched anti-inflammatory pharmaceutical composition for treatment of cutaneous dryness, itching, peeling and tightness, especially in hemodialysis patients and preparation and treatment methods thereof
US20100081637A1 (en) * 2008-10-01 2010-04-01 Innovia Skincare Corp. Eczema treatment with vitamin D and analogs thereof method, composition and cream
US20110274743A1 (en) * 2009-01-16 2011-11-10 Pharmaceutical Compounding Nz Limited Medicament for the Treatment of Pain and Inflammation
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
WO2013003803A1 (en) * 2011-06-29 2013-01-03 Avidas Pharmaceuticals Llc Topical formulations including lipid microcapsule delivery vehicles and their uses
MX2017015681A (en) 2015-06-04 2018-09-11 Pellepharm Inc Topical formulations for delivery of hedgehog inhibitor compounds and use thereof.
US20170231968A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711602A (en) * 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
US4416886A (en) * 1981-07-29 1983-11-22 Dermall Limited Method of treating pruritis and composition therefor
US4997824A (en) * 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
GB8915770D0 (en) * 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US5057500A (en) * 1990-02-12 1991-10-15 Dermatologic Research Corporation Treatment of pruritis with esters and amides
US5362719A (en) * 1990-03-01 1994-11-08 Leo Pharmaceutical Products, Ltd. A/S Lovens Kemiske Fabrik Produktionsaktieselskab) Use of vitamin-D analogues in the treatment of acne
GB9007236D0 (en) * 1990-03-30 1990-05-30 Leo Pharm Prod Ltd Chemical compounds
TW267161B (en) * 1992-11-20 1996-01-01 Hoffmann La Roche

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
GREEN, C. ET AL: "Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the tretment of psoriasis of the scalp", BRITISH JOURNAL OF DERMATOLOGY, vol. 130, no. 4, 1994, pages 483 - 487, XP000905348 *
HARRINGTON, C.I. ET AL: "Comparative effects of two different calcipotriol (MC 903)cream formulations versus placebo in psoriasis vulgaris. A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Multi-Centre study", JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, vol. 6, no. 2, 1996, pages 152 - 158, XP000905335 *
KRAGBALLE, K. ET AL: "Efficacy and safety of the 20-epi-vitamin D3 analogue KH 1060 in the topical therapy of psoriasis", ACTA DERMATO-VENEREOLOGICA, vol. 74, no. 5, September 1994 (1994-09-01), pages 398 - 402, XP000905323 *
LANGNER, A. ET AL: "A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis", BRITISH JOURNAL OF DERMATOLOGY, vol. 135, no. 3, September 1996 (1996-09-01), pages 385 - 389, XP000905347 *
LANGNER, A. ET AL: "Calcitriol ointment in th reatment of facial, hairline and retroauricular chronic plaque psoriasis", JOURNAL OF DERMATOLOGICAL TREATMENT, vol. 7, no. suppl. 1, 1996, pages S15 - S18, XP000905557 *
MENNE, T. ET AL: "Psoriasis treatment with vitamin D derivatives", SEMINARS IN DERMATOLOGY, vol. 11, no. 4, 1992, pages 278 - 283, XP000905358 *
See also references of WO9713518A1 *
VAN DE KERKHOF P.C.M.: "Vitamin D3 analogues in dermatology", H+G ZEITSCHRIFT FÜR HAUTKRANKHEITEN, vol. 69, no. 4, 1994, pages 219 - 226, XP000905356 *
VAN DER VLEUTEN, C.J.M. ET AL: "In-patient treatment with calcipotriolversus dithranol in refractory psoriasis", EUROPEAN JOURNAL OF DERMATOLOGY, vol. 5, no. 8, 1995, pages 676 - 679, XP000905336 *

Also Published As

Publication number Publication date
US5789399A (en) 1998-08-04
AU7364896A (en) 1997-04-30
WO1997013518A1 (en) 1997-04-17
US20010007866A1 (en) 2001-07-12
EP0897300A1 (en) 1999-02-24
JPH11514999A (en) 1999-12-21

Similar Documents

Publication Publication Date Title
EP0897300A4 (en) Treatment of pruritus with vitamin d and analogs thereof
HU9603369D0 (en) Treatment of vegetables
GB9310241D0 (en) Cosmetic treatment of substrates
GB9526560D0 (en) Use of 2-Amino-Heterocycles
ZA945426B (en) Treatment of tachyarrhytmias of supraventricular origin
EP0772448A4 (en) CYCLIC ANALOGS OF PTH AND PTHrP
GB9512290D0 (en) Uses of polyhexanide
ZA9610901B (en) Treatment and prophylaxis of osteoporosis
NZ300198A (en) Preparation of n-arylhydroxylamines and n-hetarylhydroxylamines
HU9402361D0 (en) New makrolides and use of them
ZA96452B (en) Dematological use of vitamin d derivatives
ZA944772B (en) Treatment of fluids
ZA96725B (en) Use of phenyclyclohexylcarboxamides
GB9202196D0 (en) Method of treatment
GB9201193D0 (en) Treatment of liquids
GB9201391D0 (en) Method of treatment
GB9216360D0 (en) Treatment of blood
IL118225A0 (en) Use of felodipine
GB9212535D0 (en) Treatment of boimass
GB9503200D0 (en) Methods of treatment
GB9522475D0 (en) Treatment of raynauds phenomenon
GB9518723D0 (en) Treatment of coccidiosis
GB9606457D0 (en) Treatment of coccidiosis
GB9503143D0 (en) Treatment of depression
GB9509396D0 (en) Treatment of gas

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/59 A

A4 Supplementary search report drawn up and despatched

Effective date: 20000518

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020319